El Hospital General Yagüe, también conocido como Residencia Sanitaria General Yagüe fue un centro hospitalario de la ciudad de Burgos, perteneciente al Seguro Obligatorio de Enfermedad.

During the past decade, Hospital General Yagüe conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 4 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital General Yagüe" #1 sponsor was "Grupo Espanol Multidisciplinario del Cancer Digestivo" with 2 trials, followed by "Spanish Breast Cancer Research Group" with 2 trials sponsored, "Asociación para el Progreso de la Oncología en Málaga" with 1 trials sponsored, "Biotronik SE & Co. KG" with 1 trials sponsored and "Clinica Universidad de Navarra, Universidad de Navarra" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital General Yagüe" #1 collaborator was "Roche Farma, S.A" with 2 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hospital General Yagüe" are "Breast Cancer" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute Stroke" (1 trials), "Arrhythmias, Cardiac" (1 trials) and "Breast Neoplasms" (1 trials). Many other conditions were trialed in "Hospital General Yagüe" in a lesser frequency.

Most popular intervention types in "Hospital General Yagüe" are "Drug" (12 trials), "Device" (3 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (2 trials), "Angioplasty (PROMUS Element™, and Xience™ Prime stent)" (1 trials), "Bevacizumab, docetaxel and doxorubicin followed by surgery" (1 trials), "Cetuximab" (1 trials) and "Citicoline" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital General Yagüe" are 15 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital General Yagüe". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Hospital General Yagüe, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital General Yagüe, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 0 trials that are defined as “Not Applicable".

Hospital General Yagüe has several departments that took part in Clinical trials: "Hospital Universitario de Burgos. Servicio de Neurología" - 5 trials